Evidence map›Paper›PMID 41773826›Full record

ArticleeLife2026

Sperm motility in mice with oligo-astheno-teratozoospermia restored by in vivo injection and electroporation of naked mRNA.

Charline Vilpreux, Paul Fourquin, Guillaume Martinez, Magali Court, Florence Appaix, Jean Luc Duteyrat, Maxime Henry, Julien Vollaire, Camille Ayad, Altan Yavuz and 18 more

Abstract read
In one paragraph

Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Testicular mRNA-LNP Delivery: A Novel Therapy for Genetic Spermatogenic Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Charline Vilpreux *Université Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Paul Fourquin *Université Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Guillaume MartinezUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.ORCID https://orcid.org/0000-0002-7572-9096
Magali CourtUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Florence AppaixUniversity Grenoble Alpes, INSERM U1209, CNRS UMR5309, Optical microscopy and cell imaging (MicroCell) facility, Institute for Advanced Biosciences, Grenoble, France.
Jean Luc DuteyratUniversité Claude Bernard Lyon 1, CNRS UAR3444, Inserm US8, ENS de Lyon, SFR Biosciences, Lyon, France.
Maxime HenryUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, plateforme Optimal, Institute for Advanced Biosciences, Grenoble, France.
Julien VollaireUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, plateforme Optimal, Institute for Advanced Biosciences, Grenoble, France.
Camille AyadUniversité Claude Bernard Lyon 1 - Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, UMR 5305, Université Lyon 1, CNRS, IBCP, Lyon, France.
Altan YavuzUniversité Claude Bernard Lyon 1 - Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, UMR 5305, Université Lyon 1, CNRS, IBCP, Lyon, France.
Geneviève ChevalierUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Lisa De MacedoUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Sofia Andrade RebeloUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Edgar Del LlanoUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Célia TebbakhUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Zine Eddine KherrafUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Emeline LambertUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Sekou Ahmed ContéUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Zeina WehbeUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Elsa GiordaniUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Veronique JosserandUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, plateforme Optimal, Institute for Advanced Biosciences, Grenoble, France.
Jacques BrocardUniversité Claude Bernard Lyon 1, CNRS UAR3444, Inserm US8, ENS de Lyon, SFR Biosciences, Lyon, France.ORCID https://orcid.org/0000-0002-0752-5737
Charles CouttonUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.ORCID https://orcid.org/0000-0002-8873-8098
Bernard VerrierUniversité Claude Bernard Lyon 1 - Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, UMR 5305, Université Lyon 1, CNRS, IBCP, Lyon, France.
Pierre F RayUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Corinne LoeuilletUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.
Christophe ArnoultUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.ORCID https://orcid.org/0000-0002-3753-5901
Jessica EscoffierUniversité Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Genetic, Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, Grenoble, France.ORCID https://orcid.org/0000-0001-8166-5845

Funding

Agence Nationale de la Recherche ANR-10-INBS-04Agence Nationale de la Recherche ANR-20-CE18-0007Fondation pour la Recherche Médicale ECO202006011669
6 · The paper itself

Abstract

Oligo-astheno-teratozoospermia (OAT), a recurrent cause of male infertility, is the most frequent disorder of spermatogenesis with a predominantly genetic origin. Patients and mice bearing mutations in the

Indexed as

AsthenozoospermiaElectroporationRNA, MessengerSperm MotilityTeratozoospermiaAnimalsElectroporation TherapiesMaleMiceSpermatozoaRNA, Messengerelectroporationinfertilityin vivo microinjectionmedicinemousemRNAprotein therapysperm cells

Identifiers

PMID41773826
PMCPMC12956281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.